CEO Robert Ford made his first purchase of company stock since March.

Shares of Abbott Laboratories ABT advanced 1.60% to $110.83 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.97% to 6,932.30 ...

Abbott Labs stock hit a 52-week low after an earnings miss, but CEO Robert Ford isn't flinching. Here is why his $2 million ...

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast higher full-year profits and steady sales growth.

Abbott missed analysts’ profit expectations for Q4 2025, yet the company’s full year financials were buoyed by strong ...

Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories stock slid Thursday after the medical-products maker reported disappointing results, hit by a slump in ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price resistance and high costs.

Investing.com - Leerink Partners has lowered its price target on Abbott Laboratories (NYSE:ABT) to $119.00 from $136.00 while maintaining a Market Perform rating, following the company’s ...